The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).
 
Erlinda Maria Gordon
Employment - Counterpoint Biomedica
Stock and Other Ownership Interests - Counterpoint Biomedica
Research Funding - AADi (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Counterpoint Biomedica
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Katherine Kim
No Relationships to Disclose
 
William W. Tseng
No Relationships to Disclose
 
Doris M Quon
Honoraria - Bioverativ; Grifols; Nobelpharma; Shire
Consulting or Advisory Role - Bayer; CSL Behring; Grifols; HEMA Biologics; Novo Nordisk; Pfizer; Shire
 
Sant P Chawla
Employment - Counterpoint Biomedica
Stock and Other Ownership Interests - AADi; Counterpoint Biomedica
Honoraria - Janssen Biotech